|
|
 |
|
|
Prasugrel, antiplatelet medicine for acute coronary syndromes,achieves class i recommendation at es by wwy yrj
|
|
|
Prasugrel, antiplatelet medicine for acute coronary syndromes,achieves class i recommendation at es by WWY YRJ
|
|
| Article Posted: 01/11/2013 |
| Article Views: 62 |
| Articles Written: 1412 - MORE ARTICLES FROM THIS AUTHOR |
| Word Count: 549 |
| Article Votes: 0 |
|
Prasugrel, antiplatelet medicine for acute coronary syndromes,achieves class i recommendation at es |
|
|
|
|
|
Business,Business News,Business Opportunities
|
|
The TRITON-TIMI 38 study comprised of a total of 10,074 patientswith chest pain at rest (UA) or suffering from NSTEMI (74 percentof the study population). In the study's combined endpoint, the relative risk ofcardiovascular death, nonfatal heart attack or nonfatal stroke , patients treated with prasugrel displayed a statisticallysignificant 18 % percent risk reduction compared with those whowere administered clopidogrel. Of all participants, 2.2 % of patients on prasugrel developed anon-CABG-related TIMI major (including life threatening and fatal)compared with 1.6% of patients on clopidogrel, with 2.3% and 1.6%of patients respectively developing non-CABG-related TIMI minor.Bleeding was significantly higher in patients treated withprasugrel vs. clopidogrel.
The clinical practice guidelines in the United States withprasugrel's Class 1B recommendation in UA/NSTEMI patients werepublished a few months following the addition of prasugrel to thejoint American Heart Association (AHA), American College ofCardiology (ACC) and the Society for Cardiovascular Angiography andInterventions (SCAI). In February 2009, the E.U. commission granted marketingauthorization for prasugrel to be co-administered withacetylsalicylic acid (ASA) to prevent atherothrombotic events inpatients with ACS undergoing primary or delayed PCI. About TRITON-TIMI 38 The TRITON-TIMI 38 trial was conducted on 13,608 patients with ACSundergoing PCI.
Compared with those treated with clopidogrel,patients who received prasugrel achieved a significant relativerisk reduction of 19 % (P 0.001) of the combined endpoint ofcardiovascular death, nonfatal heart attack or nonfatal stroke.This was primarily achieved by reducing heart attacks. The incidence of non-coronary artery bypass graft (non-CABG) TIMImajor bleeding, including fatal bleeding with prasugrel occurred in2.2 % of patients compared with 1.7% of patients on clopidogrel.Patients on prasugrel had a higher risk of serious bleedingcompared with the overall number of participants, which becameevident in three distinct patient groups that were easy toidentify, i.e. in patients weighing less than 60 kg, those aged 75years or older and in patients who had a prior history of transient ischemic attack (TIA) or stroke. For patients with a body weight of less than 60 kg the recommended treatment dose of prasugrel is5 mg.
It is generally not recommended for administration inpatients aged 75 years or older, however, should a treatment seemnecessary after careful individual benefit/risk evaluation, therecommendation should not exceed maintenance treatments of 5 mgprasugrel after a 60 mg loading dose. Prasugrel should not beadministered to patients with prior TIA or stroke. About Acute Coronary Syndromes Acute coronary syndrome includes heart attacks and unstable angina(chest pain). It can result in ACS, the single most common cause ofdeath in the E.U., accounting for more than 741,000 deaths in theEU each year and affecting over one million people annually in theU.S. Heart attacks are a major problem in coronary heart disease.
A heart attack occurs, when a blood clot partially or completelyblocks the blood supply to parts of the heart, resulting in ACS, byrupturing the plaque that has narrowed or clogged the arteriesbecause of excessive cholesterol and fat deposits. A high number of ACS patients need to have a PCIto re-open the artery, which usually includes placing a stent. Written by Petra Rattue Copyright: Medical News Today Not to be reproduced without permission of Medical News Today Additional References Citations. I am Textile Dyeing Machinery writer, reports some information about atomic alarm clocks , wood boxes wholesale.
Related Articles -
atomic alarm clocks, wood boxes wholesale,
|
Rate This Article  |
|
|
|
|
|
Do you Agree or Disagree? Have a Comment? POST IT!
| Reader Opinions |
|
|
|
|
|
|
|
|
|
| Author Login |
|
|
 |
Advertiser Login
ADVERTISE HERE NOW!
Limited Time $60 Offer!
90 Days-1.5 Million Views
|
|
TIM FAY
After 60-plus years of living, I am just trying to pass down some of the information that I have lea...more
|
|
|
|
|
LAURA JEEVES
At LeadGenerators, we specialise in content-led Online Marketing Strategies for our clients in the t...more
|
|
|
|
|
ALEX BELSEY
I am the editor of QUAY Magazine, a B2B publication based in the South West of the UK. I am also the...more
|
|
|
|
|
STEPHEN BYE
Stephen Bye is a fiction writer. His most recent novels are a 5-book “The Developer” series which be...more
|
|
|
|
|
PAUL PHILIPS
For more articles, blog messages & videos and a free e-book download go to www.NewParadigm.ws your p...more
|
|
|
|
|
LEVAL AINAH
I am an internet marketer and also an educator. My goal is to help others who are looking to improve...more
|
|
|
|
|
GENE MYERS
Author of four books and two screenplays; frequent magazine contributor. I have four other books "in...more
|
|
|
|
|
ADRIAN JOELE
I have been involved in nutrition and weight management for over 12 years and I like to share my kn...more
|
|
|
|
|
MICHAEL BRESCIANI
Rev Bresciani is the author of two Christian books. One book is an important and concisely written b...more
|
|
|
|
